Here are five points:
1. BonyPid-1000 is a doxycycline loaded synthetic bone substitute intended for bone healing in traumatic open fracture patients.
2. The trial is a randomized, single-blind controlled study and is expected to be conducted on a total of 64 patients with severe open tibia fractures.
3. The trial sites are located in Israel and Asia.
4. The first patient has been enrolled at the Tel Aviv Sourasky Medical Center in Israel.
5. PolyPid is a clinical-stage, emerging specialty pharmaceutical company.
More articles on devices:
Medtech sells two ROSA robotic systems in Georgia, Colorado
Xtant Medical announces launch for Certex — 4 things to know
Tahoe Fracture installing new MRI machine — 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
